Observation on the safety and clinical efficacy of amiodarone therapy in patients with acute heart failure complicated by arrhythmia
急性心衰合并心律失常患者采用胺碘酮治疗方式的安全性和临床效果观察

摘要

目的 探讨使用胺碘酮治疗方式对急性心衰合并心律失常患者的安全性和临床效果。方法 研究于2025年1月开始，收集样本共100例，患者均为急性心衰合并心律失常，研究结束于2026年1月。所有患者根据治疗方式不同进行分组，50例使用常规治疗的患者为对照组，其余叠加胺碘酮治疗的患者为观察组。并比较两组不同治疗方式下患者心功能指标、血压及心率指标、不良反应发生率及治疗效果。结果 经过治疗后，观察组患者心功能指标较优、血压及心率控制效果较好（P<0.05）；观察组患者不良反应发生率明显较低，治疗效果显著较优（P<0.05）。结论 使用胺碘酮治疗方式，对急性心衰合并心律失常患者来说，能够明显改善患者心功能指标，控制血压及心律水平。同时，安全性和治疗效果明显较好，是符合患者疾病治疗要求的有效药物。

Abstract

Objective To investigate the safety and clinical efficacy of amiodarone therapy in patients with acute heart failure complicated by arrhythmia.
Methods The study was conducted from January 2025, with a total of 100 cases collected, all of whom were patients with acute heart failure complicated by arrhythmia. The study concluded in January 2026. All patients were divided into groups based on different treatment modalities: 50 patients receiving conventional treatment formed the control group, while the remaining patients receiving additional amiodarone therapy formed the observation group. The cardiac function indices, blood pressure and heart rate control, incidence of adverse reactions, and therapeutic outcomes were compared between the two groups.
Results After treatment, the observation group demonstrated superior cardiac function indices, better blood pressure and heart rate control (P<0.05). The incidence of adverse reactions was significantly lower in the observation group, and the therapeutic outcomes were markedly superior (P<0.05).
Conclusion   Amiodarone therapy significantly improves cardiac function indices, blood pressure, and heart rate control in patients with acute heart failure complicated by arrhythmia. Additionally, it exhibits superior safety and therapeutic efficacy, making it an effective medication that meets the treatment requirements for these patients.